Compare Stocks: BMEA, CABA, EIKN, and AVTE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$17.89 -6.5%	$21.08	$89.95 ▼ $99.05	$518.54M	0.95	53,591 shs	1.25 million shs
BMEA Biomea Fusion	$1.78 +2.3%	$1.45	$0.87 ▼ $2.99	$126.12M	-0.23	2.22 million shs	1.54 million shs
CABA Cabaletta Bio	$2.91 +6.6%	$2.94	$1.82 ▼ $4.23	$462.86M	3.27	5.31 million shs	6.31 million shs
EIKN Eikon Therapeutics	$9.36 +4.7%	$10.33	$7.90 ▼ $17.40	$484.23M	N/A	507,323 shs	713,116 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	0.00%	-10.10%	-24.86%	+16.62%	+132.34%
BMEA Biomea Fusion	0.00%	-14.29%	+31.82%	+45.00%	-9.84%
CABA Cabaletta Bio	0.00%	-21.33%	-0.73%	-9.30%	+48.37%
EIKN Eikon Therapeutics	0.00%	-17.68%	-19.10%	-4.18%	+893,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$17.89 -6.5%	$21.08	$89.95 ▼ $99.05	$518.54M	0.95	53,591 shs	1.25 million shs
BMEA Biomea Fusion	$1.78 +2.3%	$1.45	$0.87 ▼ $2.99	$126.12M	-0.23	2.22 million shs	1.54 million shs
CABA Cabaletta Bio	$2.91 +6.6%	$2.94	$1.82 ▼ $4.23	$462.86M	3.27	5.31 million shs	6.31 million shs
EIKN Eikon Therapeutics	$9.36 +4.7%	$10.33	$7.90 ▼ $17.40	$484.23M	N/A	507,323 shs	713,116 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	0.00%	-10.10%	-24.86%	+16.62%	+132.34%
BMEA Biomea Fusion	0.00%	-14.29%	+31.82%	+45.00%	-9.84%
CABA Cabaletta Bio	0.00%	-21.33%	-0.73%	-9.30%	+48.37%
EIKN Eikon Therapeutics	0.00%	-17.68%	-19.10%	-4.18%	+893,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
BMEA Biomea Fusion	2.67	Moderate Buy	$9.00	405.62% Upside
CABA Cabaletta Bio	2.75	Moderate Buy	$15.33	426.92% Upside
EIKN Eikon Therapeutics	2.50	Moderate Buy	$25.00	167.09% Upside

Current Analyst Ratings Breakdown

Latest BMEA, CABA, EIKN, and AVTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/7/2026	EIKN Eikon Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/1/2026	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$16.00
8/24/2026	BMEA Biomea Fusion	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/24/2026	CABA Cabaletta Bio	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	EIKN Eikon Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/14/2026	CABA Cabaletta Bio	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$4.00 ➝ $3.00
8/14/2026	EIKN Eikon Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Underperform	$5.00 ➝ $4.00
8/3/2026	EIKN Eikon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E-) ➝ Sell (E)
7/17/2026	CABA Cabaletta Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/1/2026	BMEA Biomea Fusion	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/16/2026	BMEA Biomea Fusion	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$0.42 per share	N/A
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$1.16 per share	N/A
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	N/A
BMEA Biomea Fusion	-$61.80M	-$0.29	N/A	N/A	N/A	N/A	-253.73%	-97.91%	11/3/2026 (Estimated)
CABA Cabaletta Bio	-$167.86M	-$1.57	N/A	N/A	N/A	N/A	-128.27%	-95.47%	11/9/2026 (Estimated)
EIKN Eikon Therapeutics	-$324.25M	-$4.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest BMEA, CABA, EIKN, and AVTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CABA Cabaletta Bio	-$0.3729	-$0.34	+$0.0329	-$0.34	$1.67 million	N/A
8/13/2026	Q2 2026	EIKN Eikon Therapeutics	-$1.61	-$1.63	-$0.02	-$1.63	N/A	N/A
8/6/2026	Q2 2026	BMEA Biomea Fusion	-$0.2235	-$0.12	+$0.1035	-$0.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTE Aerovate Therapeutics	N/A	8.78	8.78
BMEA Biomea Fusion	N/A	3.47	3.47
CABA Cabaletta Bio	N/A	5.79	5.79
EIKN Eikon Therapeutics	N/A	9.89	9.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTE Aerovate Therapeutics	N/A
BMEA Biomea Fusion	96.72%
CABA Cabaletta Bio	N/A
EIKN Eikon Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AVTE Aerovate Therapeutics	24.90%
BMEA Biomea Fusion	10.60%
CABA Cabaletta Bio	6.44%
EIKN Eikon Therapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
BMEA Biomea Fusion	50	72.48 million	64.80 million	Optionable
CABA Cabaletta Bio	158	169.55 million	158.63 million	Optionable
EIKN Eikon Therapeutics	384	54.17 million	N/A	N/A

BMEA, CABA, EIKN, and AVTE Headlines

Recent News About These Companies

Eikon Therapeutics (NASDAQ:EIKN) Stock Price Up 6.9% After Insider Buying Activity

September 11 at 1:21 AM | americanbankingnews.com

Inhibrx, Eikon rise after insider buying

September 9, 2026 | msn.com

Eikon Therapeutics (NASDAQ:EIKN) Trading Up 6.9% After Insider Buying Activity

September 9, 2026 | marketbeat.com

Eikon Therapeutics (NASDAQ:EIKN) Raised to Strong-Buy at Mizuho

September 9, 2026 | marketbeat.com

Major Investor Makes Bold Move on Eikon Therapeutics Shares

September 8, 2026 | tipranks.com

Group Iv Gp Lp Column Buys 89,200 Shares of Eikon Therapeutics (NASDAQ:EIKN) Stock

September 8, 2026 | marketbeat.com

Eikon Therapeutics Appoints Ching-Pin Chang As Executive VP & Chief Scientific Officer

September 3, 2026 | rttnews.com

Eikon Therapeutics Appoints CP Chang as Executive Vice President and Chief Scientific Officer

September 3, 2026 | quiverquant.comQ

Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer

September 3, 2026 | globenewswire.com

Comprehensive Financial Management LLC Purchases New Shares in Eikon Therapeutics, Inc. $EIKN

September 2, 2026 | marketbeat.com

BlackRock Inc. Buys 962,046 Shares of Eikon Therapeutics, Inc. $EIKN

September 1, 2026 | marketbeat.com

Eikon Therapeutics to Participate in Investor Conferences in September 2026

August 26, 2026 | globenewswire.com

Parkman Healthcare Partners LLC Purchases New Shares in Eikon Therapeutics, Inc. $EIKN

August 25, 2026 | marketbeat.com

Eikon Therapeutics, Inc. (NASDAQ:EIKN) Receives Average Recommendation of "Hold" from Brokerages

August 24, 2026 | marketbeat.com

Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004

August 22, 2026 | marketbeat.com

Transcript : Eikon Therapeutics, Inc. - Special Call

August 22, 2026 | zonebourse.comZ

Eikon Therapeutics, Inc. (EIKN) Discusses Advances in PARP1 Biology and Next-Generation PARP Inhibitors in Oncology Transcript

August 22, 2026 | seekingalpha.com

Eikon Therapeutics Inc (EIKN)

August 21, 2026 | investing.com

Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald

August 18, 2026 | globenewswire.com

Eikon Therapeutics Highlights Q3 2026 Oncology Pipeline Progress

August 16, 2026 | theglobeandmail.com

Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

August 13, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA, CABA, EIKN, and AVTE Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

$17.89 -1.25 (-6.53%)

As of 09/11/2026

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Biomea Fusion NASDAQ:BMEA

$1.78 +0.04 (+2.30%)

Closing price 04:00 PM Eastern

Extended Trading

$1.82 +0.03 (+1.97%)

As of 07:45 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Cabaletta Bio NASDAQ:CABA

$2.91 +0.18 (+6.59%)

Closing price 04:00 PM Eastern

Extended Trading

$2.97 +0.06 (+1.92%)

As of 07:56 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Eikon Therapeutics NASDAQ:EIKN

$9.36 +0.42 (+4.70%)

Closing price 04:00 PM Eastern

Extended Trading

$9.35 -0.01 (-0.16%)

As of 07:30 PM Eastern

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers. Our Chair and Chief Executive Officer, Dr. Roger M. Perlmutter, M.D., Ph.D., and our Chief Medical Officer, Dr. Roy Baynes, M.D., Ph.D., together have a proven track record of identifying, developing, and commercializing some of the most impactful drugs ever brought to market, including pembrolizumab, currently the world’s best-selling oncology therapeutic and arguably the most important anti-neoplastic agent ever introduced into clinical practice. While Drs. Perlmutter and Baynes’ track records do not provide a guarantee of future clinical success, and any products developed by us may not achieve the regulatory or commercial success of products that Drs. Perlmutter and Baynes were previously involved in developing, their experience provides valuable insight and strategic guidance to our drug development efforts. Our broader leadership team consists of former senior leaders at global pharmaceutical companies, who have successfully collaborated across several decades on the discovery, development, and commercialization of over 100 new molecular entities. Our strategy centers around deploying our technology platform, including our proprietary single molecule tracking, or SMT, system, to develop internally-derived novel therapies, while also leveraging the deep expertise of our management team to opportunistically in-license promising assets. Our most advanced product candidate, EIK1001, a toll-like receptor, or TLR, 7/8 dual-agonist, is currently in a global Phase 2/3 registrational trial in combination with pembrolizumab for the treatment of patients with advanced melanoma. This Phase 2/3 trial is designed to proceed to completion, subject to interim analysis by a data monitoring committee, and to form the basis for registration. We are also evaluating EIK1001 in combination with both pembrolizumab and histology appropriate chemotherapy for the treatment of patients with non-small cell lung cancer, or NSCLC, in a Phase 2 trial, as well as a Phase 2/3 registrational trial for which we recently initiated site selection. We are also conducting Phase 1/2 trials of each of our selective PARP1 inhibitor product candidates, EIK1003 and EIK1004, in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant candidate EIK1004, to address brain metastases and primary brain malignancies. In addition, we have recently initiated a Phase 1/2 trial in patients with advanced solid tumors for EIK1005, our Werner, or WRN, helicase inhibitor that emerged through internal research using our technology platform, which will ultimately be evaluated for the treatment of patients with microsatellite instability-high, or MSI-high, tumors. We were incorporated in Delaware in July 2019. Our principal executive offices are located in Millbrae, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMEA, CABA, EIKN, and AVTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMEA, CABA, EIKN, and AVTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMEA, CABA, EIKN, and AVTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA, CABA, EIKN, and AVTE Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

Biomea Fusion NASDAQ:BMEA

Cabaletta Bio NASDAQ:CABA

Eikon Therapeutics NASDAQ:EIKN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMEA, CABA, EIKN, and AVTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMEA, CABA, EIKN, and AVTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMEA, CABA, EIKN, and AVTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA, CABA, EIKN, and AVTE Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

Biomea Fusion NASDAQ:BMEA

Cabaletta Bio NASDAQ:CABA

Eikon Therapeutics NASDAQ:EIKN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools